Shares of US Stem Cell Inc (OTCMKTS:USRM) began to stabilize this week on the heels of a rather large consolidation that affected the stock over a period of several trading days following its huge February price explosion.

From February 1st to March 1st, USRM shares traded from a low of .0024 all the way up to .0599, which represents a dizzying increase of 2395% while volume during that same period was as high as it had ever been over the life of the stock. In the week to follow, USRM would see an unsurprising pull back off of that impressive high, and appears to have found support for the time being.

US Stem Cell Inc (OTCMKTS:USRM) published a PR earlier in the week alluding to the appointment of a new board member- one who had a preexisting relationship with the company. You can read more about that appointment further down the page.

About US Stem Cell

US Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. It is focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The companys business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from the businesses will, over time, provide funds to support clinical development activities. The company believes the combination of its own therapeutics pipeline combined with its revenue generating capabilities provides a unique opportunity for growth and a pathway to profitability.

US Stem Cell Appoints New Board Member

This week, the US Stem Cell announced that Greg Knutson, the Manager of NorthStar Biotech, LLC, has joined the Board of Directors of U.S. Stem Cell, Inc.

We are very pleased that Greg Knutson, a longtime supporter of the U.S. Stem Cell family of companies, has agreed to join our Board and assist us to continue with our recent technological advances and financial accomplishments, said Mike Tomas, President and CEO of U.S. Stem Cell, Inc.

A longtime U.S. Stem Cell shareholder and supporter, Knutson brings more than 30 years of business and financial experience to the organization. During his entrepreneurial career, Knutson founded Concrete Specialists, Inc. and continues to serve as its President; is the founder and current President of Sunwood Properties; and is the founder and Managing Partner of G&G Land Development, LLC.

Demonstrating a progressive step forward, Knutson joins the Board of Directors just as the two companies amicably settled a legal dispute related to NorthStars preferred shares. (Source: Accesswire)

On a clear downside, USRM has a miniscule market value of just $1.6 million at current pricing. That being said, the sheer intensity of the mega-run we witnessed in February and the fact that the PPS appears to be stabilizing after a large consolidation, is enough to keep our interest. At whatever point the stock ultimately launches a solid recovery, there will almost certainly be opportunities opening up for traders. Were going to continue to track USRM and its progress on the chart, and keep a sharp eye out for new updates. Stay up to date on USRM right here on Street Register. We encourage you to sign up for our 100% free penny stock newsletter, by simply submitting your active email address in the box

Visit link:
US Stem Cell Inc (OTCMKTS:USRM) Finding Support After ... - Street Register